Drug Trial Radar · NCT07644832
An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
76
Planned (sponsor's estimate)
Start
May 31, 2024
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Shanghai RAAS Blood Products Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, immunogenicity , PK, and PD of a single dose of SR604 in participants with Hemophilia A or Hemophilia B, with or without inhibitors (Part A)and to evaluate the safety, PK, PD, and efficacy of multiple doses of SR604 in participants with Hemophilia A or Hemophilia B, or Factor VII (FVII) deficiency, with or without inhibitors (Part B and Part C).
Conditions
- Hemophilia A
- Hemophilia B
- Factor VII Deficiency
Interventions
SR604Drug
SR604 will be administered as SC injection
SR604Drug
SR604 will be administered as SC injection.
SR604Drug
SR604 will be administered as SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Incidence of AEs/SAEs/AESITime frame: Part A: From Baseline (Day 1) up to Day 85
- PartA: Incidence of drug-related AEs/SAEs/AESIsTime frame: Part A: From Baseline (Day 1) up to Day 85
- Part A: Number and incidence of patients with anti-drug antibodies (ADA) and neutralizing antibodiesTime frame: Part A: From Baseline (Day 1) up to Day 85
- Part B/ Part C:Treated total annualized bleeding rate (ABR)Time frame: Part B: From Baseline (Day 1) up to Day 211;Part C: From baseline (Day 1) up to Day 393
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Xiangya Hospital of Central South University
Changsha, China · Recruiting
The First Affiliated Hospital of University of Science and Technology of China
Hefei, China · Recruiting
Jinan Central Hospital
Jinan, China · Recruiting
The First Hospital of Lanzhou University
Lanzhou, China · Recruiting
Ruijin Hospital Shanghai Jiaotong University School of Medicine
Shanghai, China · Completed
The Second Hospital of Shanxi Medical University
Taiyuan, China · Recruiting
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, China · Completed
Xian Central Hospital
Xi'an, China · Recruiting
Zhengzhou People's Hospital
Zhengzhou, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.